Beximco Pharmaceuticals Limited (BXP.L) Stock
Beximco Pharmaceuticals Limited

Company profile
Beximco Pharmaceuticals reported revenue of 44.39 billion BDT for fiscal year 2024, up 13.1% from fiscal year 2023, and net income of 5.83 billion BDT. That is a net profit margin of 13.1% for fiscal year 2024. In Q2 2025 (the quarter ended December 31, 2024) revenue was 12.30 billion BDT, up 12.8% from a year before. In Q2 2025 it reported net income of 1.83 billion BDT, against net income of 1.43 billion BDT a year earlier. Our analysis of its filings shows revenue growing from 34.67 billion BDT in fiscal year 2022 to 44.39 billion BDT in fiscal year 2024, 13.2% a year on average. Beximco Pharmaceuticals reports about 6,000 full-time employees.
What stands out
- Revenue and net income in fiscal year 2024 were the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended June 30, 2024.
About Beximco Pharmaceuticals Limited
Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh and internationally. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It offers products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. Beximco Pharmaceuticals PLC. was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.
Leadership
- Mohammad Ali Nawaz C.M.A. — Chief Financial Officer
- S. M. Rabbur Reza — Chief Operating Officer
- Jamal Ahmed Choudhury — Director of Accounts & Finance
- Rizvi Ul Kabir — Director of Marketing
- M. A. Arshad Bhuiyan — General Manager of Human Resources
How much revenue does Beximco Pharmaceuticals make?
Beximco Pharmaceuticals reported 44.39 billion BDT in revenue for fiscal year 2024, up 13.1% from 39.27 billion BDT in fiscal year 2023. In Q2 2025 revenue was 12.30 billion BDT.
What companies are similar to Beximco Pharmaceuticals?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Grifols, S.a. (0RDV.IL), Hikma Pharmaceuticals PLC (HIK.L), International Biotechnology Ord (IBT.L), Venture Life Group plc (VLG.L).
How has Beximco Pharmaceuticals' revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2020, 25.61 billion BDT; FY2021, 29.49 billion BDT; FY2022, 34.67 billion BDT; FY2023, 39.27 billion BDT; FY2024, 44.39 billion BDT.
Company Information
Data as of .
How to cite: DataPorium, “Beximco Pharmaceuticals Limited (BXP.L)”, data as of Dec 31, 2024, https://dataporium.tech/stocks/BXP.L